Max Cummings, PhD

Max Cummings is the Founder and President of The Dinosaur Project, LLC, providing computational chemistry and cheminformatics services to industrial and academic clients. He has more than thirty-five years of experience in pharmaceutical discovery. Prior to starting his own consultancy he worked as a computational chemist in both large and small companies in the USA, Europe and Canada. Dr. Cummings has made significant contributions to the discovery and development of multiple clinical candidates, including the approved Hepatitis C drug Olysio. He is a co-author on sixty-five peer-reviewed publications and five book chapters, and a co-inventor on more than twenty issued patents.

Formerly:

Senior Principal Scientist, Janssen R&D, Spring House, USA

Principal Scientist, Tibotec BVBA, Mechelen, Belgium

Senior Scientist, 3-Dimensional Pharmaceuticals, Exton, USA

Investigator, SmithKline Beecham Pharmaceuticals, King of Prussia, USA

Scientist, SynPhar Laboratories, Edmonton, Canada